Erasca, Inc. (ERAS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Erasca, Inc.
Address
3115 Merryfield Row
San Diego, CA 92121
United States of America (the)
Phone
858 465 6511
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
July 16, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | 1.16M | 1972 |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 93,181 | 1958 |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary | 607,440 | 1972 |
| Shannon Morris | Chief Medical Officer | 772,700 | 1970 |
| David Chacko | Chief Financial Officer & Chief Business Officer | 775,216 | 1983 |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer | 0 | 1971 |
| Lisa Tesvich-Bonora | Chief People Officer | 0 | N/A |
| Brian L. Baker | Senior Vice President of Finance | 0 | 1967 |
| Robert Shoemaker | Chief Scientific Officer | 0 | 1981 |
| Alison Tjosvold Milhous | Senior Vice President of Accounting | 0 | 1979 |
| Nik Chetwyn | Chief Operating Officer | 0 | N/A |
Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
